EFFECTS OF CABERGOLINE TREATMENT ON METABOLIC SYNDROME AND VISCERAL ADIPOSITY INDEX IN PATIENTS WITH HYPERPROLACTINEMIA.

Introduction: Hyperprolactinemia is reportedly associated with an impaired metabolic profile, particularly in patients with concomitant hypogonadism. The current study aimed at investigating the effects of short (12 months) and long (60 months) treatment with cabergoline (CAB) on metabolic complications, metabolic syndrome (MS) prevalence and visceral adiposity index (VAI) in hyperprolactinemic patients (pts). Patients and Methods: Seventy-one pts (51 F, 20 M, aged 35.4±11.7 yrs), including 36 with microprolactinomas, 32 with macroprolactinomas and 3 with non-tumoral hyperprolactinemia, entered the study. In all pts, PRL and metabolic parameters (BMI, waist circumference, lipid and glucose …